Q1 FY27 results approved; Re 1 final dividend; books closed Sept 19-25
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.5 pts less than Nifty Microcap 250 and 8.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medicamen Biotech posted Q1 FY27 standalone revenue of Rs 4,471 lakh (up about 15% YoY) and PAT of Rs 253 lakh (up about 54% YoY). Consolidated PAT was Rs 185 lakh. Board approved a Re 1 per share final dividend (10%) subject to AGM nod. Register of members closed Sept 19-25 for the 33rd AGM on Sept 26 via video conferencing. Auditor issued unmodified review report. Minor fines of about Rs 1.1 lakh each from BSE and NSE for past board composition lapses were already paid in June 2026.
Strong profit growth and dividend cheer; minor past governance fine already settled, no fresh overhang.